Vita Life Sciences Projects $45m-$46m Sales, Up 16% in H1 2025
Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.
- H1 2025 sales guidance of $45.0m-$46.0m, up 14-16% from prior year
- Pre-tax profit expected between $6.2m and $6.7m, slightly higher than H1 2024
- Core markets Australia, Malaysia, and Singapore show robust growth
- Sales in China decline compared to prior period despite new distributor efforts
- Strategic investments in brands and marketing to support long-term growth
Strong Growth in Core Markets
Vita Life Sciences (ASX, VLS) has released guidance for the half year ending 30 June 2025, forecasting a promising increase in sales and profits. The company anticipates revenue between $45.0 million and $46.0 million, representing a 14 to 16 percent rise compared to the same period last year. This growth is primarily fueled by solid demand in its key markets of Australia, Malaysia, and Singapore, where the company’s nutritional supplements continue to gain traction.
Profitability Edges Higher Amid Strategic Spending
Pre-tax profit is expected to range from $6.2 million to $6.7 million, a modest improvement over the $6.0 million recorded in the first half of 2024. Vita Life Sciences is deliberately investing in brand development, sales channels, and marketing capabilities. These expenses, while impacting short-term profitability, are designed to strengthen the company’s competitive position and unlock long-term shareholder value.
China Market Challenges
Despite the overall positive outlook, the company acknowledges a setback in China, where sales are projected to be lower than the prior corresponding period. The new distributor in China is still building momentum, but the market remains challenging. This contrast highlights the uneven nature of Vita Life Sciences’ geographic performance and underscores the importance of its core markets in sustaining growth.
Looking Ahead
Managing Director Andrew O’Keefe expressed confidence in maintaining the momentum into the second half of the year, as ongoing sales initiatives continue to gain traction. The company remains committed to its long-term strategy focused on sustainable growth and value creation for shareholders, balancing short-term investments with future opportunities.
Bottom Line?
Vita Life Sciences’ growth story hinges on core markets and strategic investments, but China’s performance remains a watchpoint.
Questions in the middle?
- How quickly can the new Chinese distributor reverse the sales decline?
- What impact will ongoing marketing investments have on second-half profitability?
- Are there plans to expand into new markets beyond the current core regions?
